The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...

Jürgen Drews returned to the spotlight in a special edition of the "Giovanni Zarrella Show". During the recording of the ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe. The FDA has accepted two separate marketing ...

A recent eGastroenterology review by Professor Intissar Anan highlights major breakthroughs in transthyretin amyloidosis ...

In spite of extreme complications like pneumonia, septic shock, and polyneuropathy, the multidisciplinary team - consisting ...

Transthyretin amyloidosis (ATTR) is caused by the misfolding and aggregation of the transthyretin (TTR) protein, leading to multi-organ damage.

See the latest Intellia Therapeutics Inc stock price (NTLA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Put together with a forward by David Wise in 2025. This is basically a kind of requiem for Jack de Montreuil as much of the ...

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and 2 diabetes. It is a leading cause of lower-limb amputation and disabling neuropathic pain. Amputations in patients with ...